Congestive heart failure historical perspective: Difference between revisions
Jump to navigation
Jump to search
| Line 30: | Line 30: | ||
* In 1918 E.H. Starling described his ‘Law of the Heart’ which forms the basis of modern Frank-Starling curves. | * In 1918 E.H. Starling described his ‘Law of the Heart’ which forms the basis of modern Frank-Starling curves. | ||
=== | === 1940's-1960's === | ||
* In the 1940s and 1960s the advent of cardiac catheterisation and cardiac surgery furthered our understanding of HF. | * In the 1940s and 1960s the advent of cardiac catheterisation and cardiac surgery furthered our understanding of HF. | ||
| Line 39: | Line 39: | ||
* The 1960s was also the decade that saw the emergence of LV assist devices (LVADs), beginning in 1961 when Dennis and co-workers uses a roller pump to assist the left ventricle. | * The 1960s was also the decade that saw the emergence of LV assist devices (LVADs), beginning in 1961 when Dennis and co-workers uses a roller pump to assist the left ventricle. | ||
=== | === 1970's-1980's === | ||
* From the mid-1970s, the availability of vasodilators provided a means to reduce afterload in order to increase cardiac efficiency and cardiac output in HF | * From the mid-1970s, the availability of vasodilators provided a means to reduce afterload in order to increase cardiac efficiency and cardiac output in HF | ||
*In 1986, The Vasodilator-Heart Failure Trial (V-HeFT I), was conducted by J. Cohn and colleagues and demonstrated that, despite short-term hemodynamic improvement, afterload reduction alone may benefit patients in the form of improved survival. | |||
*In 1980's HF became recognized as a neuroendocrine disease. The chronic activation of renin-angiotensin-aldosterone system and increase in catecholamines in untreated HF patients became known to scientists. | |||
*As a result, angiotensin converting enzyme inhibitors (ACEIs) and beta-blockers were successfully introduced as a treatment for HF. | |||
*Later, pharmacological therapies which counter the unchecked RAAS activation such as spironolactone were also introduced as add-on therapies to ACEI and beta-blockers. | |||
=== 1990's === | |||
Revision as of 16:37, 4 March 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Historical Perspective
Ancient Times
- Italian Egyptologist Ernesto Schiaparelli reported the first case of decompensated heart failure (HF) in the remains of a tomb in the Valley of the Queens over 3500 years ago the remains are now housed in the Egyptian museum in Turin, Italy. They belonged to an Egyptian dignitary named Nebiri who lived under the reign of the 18th dynasty Pharaoh Thutmose III (1479–24 BC).
- Andreas Nerlich, a pathologist from Munich, Germany, demonstrated the presence of pulmonary oedema by examining histopathological findings in the lungs.
- Various other features of HF such as cardiac hypertrophy and coronary atherosclerosis were also known to Egyptians.
- In China, ‘the Yellow Emperor’s Classic of Internal Medicine’ described edema as early as 2600 B.C.
- Greek and Roman texts also contain descriptions of HF, although edema, dyspnea and anasarca, the most common manifestations described in these texts, could be attributed to other causes than HF.
- Hippocratic corpus while describing rales, a common finding in HF patients as: ‘When the ear is held to the chest, and one listens for some time, it may be heard to see the inside like the boiling of vinegar’ (translation by A. Katz). He also demonstrated a method to drain this fluid through a hole drilled in the ribcage. However, at that time, there seem to have been no understanding about why the fluid had accumulated.
- Erophilus and Erasistratus performed human dissections and experiments and commented that the heart contracts but believed that the arteries contained air and that blood was confined to the veins.
- Even Galen, a Greek physician during the second century was of the view that the heart was just a source of heat failing to understand its role as a pump. He almost certainly described atrial fibrillation (AF) and indeed palpated the arterial pulse, a technique that had been used for prognosis millennia earlier by the Egyptians.However, Galen believed that the pulse was transmitted by the arterial walls rather than by blood flowing through the lumen.
- The medieval Arab scholar Ibn Sina, known to the West as Avicenna (980–1037), had a reputation as an authority on heart disease. His treatise entitled ‘Kitab al-Adviyt-al-Qalbiye’ or ‘The book on drugs for cardiac diseases’ discusses therapies for difficulty in breathing, palpitation, and syncope. Widely used in the West in a Latin translation in the 14th century, the treatise remains in the Galenic tradition of humours.
Recognition of the Heart's Pump Function (17th to 20th Century)
- In 1628 when William Harvey clearly described circulation and elucidated hemodynamic abnormalities occurring in HF.
- A few years later, a description of HF due to tamponade and to mitral stenosis was published.
- In the mid-18th century, Lancisi noted that valvular regurgitation leads to ventricular dilatation, which weakens the heart but he appreciated that the ventricle cavity does not enlarge in aortic stenosis.
- Subsequently, the occurrence of cardiac hypertrophy, both eccentric and concentric, and the existence of acute and chronic HF as well as the role of adaptive and maladaptive changes in the failing heart were described. Bedside examination techniques such as palpation, percussion, and auscultation were used to confirm these findings.
- Röntgen discovered x-rays in 1895 and allowed a more thorough understanding of maladaptive changes occurring in HF patients.
- Distinction between the various forms of cardiac enlargement continued into the 20th century.
- In 1918 E.H. Starling described his ‘Law of the Heart’ which forms the basis of modern Frank-Starling curves.
1940's-1960's
- In the 1940s and 1960s the advent of cardiac catheterisation and cardiac surgery furthered our understanding of HF.
- In the decades before the 1980s, the only attempt to explain the changes occurring in HF was related to the back/forward theories and treatment was based on bed rest, inactivity and fluid restriction.
- On the pharmacological side, only digitalis and diuretics were prescribed, and HF research often concentrated more on the kidney than on the heart. With the description of ‘Families of Starling Curves’ by S.J. Sarnoff the idea of contractility came about, based on the possibility of shifting from one curve to another, and the ‘contractile’ state of the heart became a major regulator of cardiac performance.
- Research was concentrated on understanding the cause of low contractility in HF. Thus, the role of energy starvation and abnormal calcium movement gained rapid popularity and stimulated efforts to develop inotropic drugs that were more powerful than digitalis. However, all clinical trials of inotropic drugs were stopped prematurely because the agents did more harm than good and none had a positive effect on survival.
- A few years later, cardiac glycosides were also found not to improve survival in patients with HF in sinus rhythm.
- The 1960s was also the decade that saw the emergence of LV assist devices (LVADs), beginning in 1961 when Dennis and co-workers uses a roller pump to assist the left ventricle.
1970's-1980's
- From the mid-1970s, the availability of vasodilators provided a means to reduce afterload in order to increase cardiac efficiency and cardiac output in HF
- In 1986, The Vasodilator-Heart Failure Trial (V-HeFT I), was conducted by J. Cohn and colleagues and demonstrated that, despite short-term hemodynamic improvement, afterload reduction alone may benefit patients in the form of improved survival.
- In 1980's HF became recognized as a neuroendocrine disease. The chronic activation of renin-angiotensin-aldosterone system and increase in catecholamines in untreated HF patients became known to scientists.
- As a result, angiotensin converting enzyme inhibitors (ACEIs) and beta-blockers were successfully introduced as a treatment for HF.
- Later, pharmacological therapies which counter the unchecked RAAS activation such as spironolactone were also introduced as add-on therapies to ACEI and beta-blockers.